The company is also initiating activities to reduce its corporate facilities footprint by either subletting a significant portion of its leased space or subletting the entirety of its building and relocating to smaller facilities. The company expects annualized cost savings of about $20 million while incurring $3 million in pretax charges for severance and other costs related to the restructuring, primarily in 2019. On The Radar Clinical Trial Readouts Adverum Biotechnologies Inc (NASDAQ: ADVM ) will present additional Phase 1 data for ADVM-022 in wet age-related macular degeneration at the American Academy of Ophthalmology, or AAO, 2019 in San Francisco, California. Regenxbio Inc (NASDAQ: RGNX ) is due to present Phase 1/2a data for RGX-314 in wet AMD at the AAO 2019 meeting. Kodiak Sciences Inc (NASDAQ: KOD ) is scheduled to present Phase 1b data for KSI-301 in diabetic macular edema at the Retina Subspecialty Day.